Abstract
Tuberculosis is a serious global health problem caused by the bacterium Mycobacterium tuberculosis. There is an urgent need for discovery and development of new treatments, but this can only be accomplished through rapid and reproducible M. tuberculosis assays designed to identify potent inhibitors. We developed an automated 96-well assay utilizing a recombinant strain of M. tuberculosis expressing a far-red fluorescent reporter to determine the activity of novel compounds; this allowed us to measure growth by monitoring both optical density and fluorescence. We determined that optical density and fluorescence were correlated with cell number during logarithmic phase growth. Fluorescence was stably maintained without antibiotic selection over 5 days, during which time cells remained actively growing. We optimized parameters for the assay, with the final format being 5 days’ growth in 96-well plates in the presence of 2% w/v DMSO. We confirmed reproducibility using rifampicin and other antibiotics. The dual detection method allows for a reproducible calculation of the minimum inhibitory concentration (MIC), at the same time detecting artefacts such as fluorescence quenching or compound precipitation. We used our assay to confirm anti-tubercular activity and establish the structure activity relationship (SAR) around the imidazo[1,2-a]pyridine-3-carboxamides, a promising series of M. tuberculosis inhibitors.
Highlights
More than one third of the world’s population is infected with Mycobacterium tuberculosis and nearly 1.5 million people died from tuberculosis in 2010 [1]
The high burden of tuberculosis infections in regions with limited health care resources has led to frequent treatment interruption and subsequent failure resulting in the rise of multidrug resistant (MDR), and extensively drug resistant (XDR) strains
Totally drug resistant (TDR) strains of M. tuberculosis have been isolated highlighting the urgency for the development of new treatments [2]
Summary
More than one third of the world’s population is infected with Mycobacterium tuberculosis and nearly 1.5 million people died from tuberculosis in 2010 [1]. The high burden of tuberculosis infections in regions with limited health care resources has led to frequent treatment interruption and subsequent failure resulting in the rise of multidrug resistant (MDR), and extensively drug resistant (XDR) strains. A number of drug candidates with anti-tuberculosis activity are currently in pre-clinical and clinical development [3] [4] [5]. Many of these drug candidates are derivatives of current anti-tubercular drugs or they target the same cellular process and are likely to help only with the treatment of drug sensitive M. tuberculosis infections [6] [7]. To be able to successfully tackle the problem of drug resistant M. tuberculosis we need novel compounds that target novel biological pathways in M. tuberculosis, shorten therapy, and reduce the burden of latent infection [8]
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have